UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A delicate balance – The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics

Biochemical pharmacology, 2019-04, Vol.162, p.250-261

2019

Volltextzugriff (PDF)

New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia

Cellular signalling, 2014-01, Vol.26 (1), p.149-161

2014

Volltextzugriff (PDF)

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

Clinical cancer research, 2019-11, Vol.25 (22), p.6815-6826

2019

Volltextzugriff (PDF)

Targeting mitochondrial respiration for the treatment of acute myeloid leukemia

Biochemical pharmacology, 2020-12, Vol.182, p.114253-114253, Article 114253

2020

Volltextzugriff (PDF)

Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51

PloS one, 2013-11, Vol.8 (11), p.e79106

2013

Volltextzugriff (PDF)

COVID‐19 and childhood acute lymphoblastic leukemia

Pediatric blood & cancer, 2020-07, Vol.67 (7), p.e28400-n/a

2020

Volltextzugriff (PDF)

Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

Signal transduction and targeted therapy, 2020-12, Vol.5 (1), p.288-288, Article 288

2020

Volltextzugriff (PDF)

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

Clinical cancer research, 2016-09, Vol.22 (17), p.4440-4451

2016

Volltextzugriff (PDF)

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

Haematologica (Roma), 2019-11, Vol.104 (11), p.2225-2240

2019

Volltextzugriff (PDF)

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

Journal of clinical oncology, 2012-10, Vol.30 (29), p.3625-3632

2012

Volltextzugriff (PDF)

Mindfulness and dynamic functional neural connectivity in children and adolescents

Behavioural brain research, 2018-01, Vol.336, p.211-218

2018

Volltextzugriff (PDF)

Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax

Biochemical pharmacology, 2024-10, Vol.228, p.116065, Article 116065

2024

Volltextzugriff (PDF)

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

Haematologica (Roma), 2021-05, Vol.106 (5), p.1262-1277

2021

Volltextzugriff (PDF)

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial

Blood, 2017-06, Vol.129 (25), p.3304-3313

2017

Volltextzugriff (PDF)

Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer

PloS one, 2012-12, Vol.7 (12), p.e52095

2012

Volltextzugriff (PDF)

Curing childhood cancer the “Natural” Way: Nature as the source of chemotherapy agents

Biochemical pharmacology, 2023-07, Vol.213, p.115630, Article 115630

2023

Volltextzugriff (PDF)

Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1

Journal of cellular and molecular medicine, 2018-12, Vol.22 (12), p.6099-6111

2018

Volltextzugriff (PDF)

Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo

Biochemical pharmacology, 2018-02, Vol.148, p.13-26

2018

Volltextzugriff (PDF)

c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia

Apoptosis (London), 2022-12, Vol.27 (11-12), p.913-928

2022

Volltextzugriff (PDF)

The G.O.A.T. Diagnosis: A Rare and Uncommon Diagnosis of Macrocytic Anemia

Clinical pediatrics, 2024-06, p.99228241257097-99228241257097

2024

Volltextzugriff (PDF)

The evolution and history of Vinca alkaloids: From the Big Bang to the treatment of pediatric acute leukemia

Pediatric blood & cancer, 2024-08, Vol.71 (11), p.e31247

2024

Volltextzugriff (PDF)

The paradox of Myeloid Leukemia associated with Down syndrome

Biochemical pharmacology, 2022-07, Vol.201, p.115046-115046, Article 115046

2022

Volltextzugriff (PDF)

Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML

Leukemia research, 2024-09, Vol.144, p.107547, Article 107547

2024

Volltextzugriff (PDF)

Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms

Biochemical pharmacology, 2023-10, Vol.216, p.115759-115759, Article 115759

2023

Volltextzugriff (PDF)

1 – 25 von 381

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(341)
Mit Volltextzugriff
(329)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(380)
Japanisch
(37)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(229)
Life Sciences & Biomedicine
(217)
Humans
(181)
Oncology
(91)
Female
(85)
Male
(83)
Hematology
(78)
Child
(71)
Pediatrics
(62)
Biological And Medical Sciences
(51)
Medical Sciences
(48)
Child, Preschool
(47)
Acute Myeloid Leukemia
(41)
Adolescent
(37)
Down Syndrome - Complications
(37)
Leukemia
(34)
Infant
(31)
Chemotherapy
(29)
Hematologic And Hematopoietic Diseases
(27)
Animals
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(60)
Pediatric Blood & Cancer
(15)
Cancer Research
(12)
Clinical Cancer Research
(12)
Plos One
(10)
Journal Of Pediatric Hematology/oncology
(9)
Biochemical Pharmacology
(8)
Cancer
(7)
The Journal Of Biological Chemistry
(7)
Journal Of Clinical Oncology
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A delicate balance – The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics

New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

Targeting mitochondrial respiration for the treatment of acute myeloid leukemia

Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51

COVID‐19 and childhood acute lymphoblastic leukemia

Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

Mindfulness and dynamic functional neural connectivity in children and adolescents

Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial

Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer

Curing childhood cancer the “Natural” Way: Nature as the source of chemotherapy agents

Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1

Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo

c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia

The G.O.A.T. Diagnosis: A Rare and Uncommon Diagnosis of Macrocytic Anemia

The evolution and history of Vinca alkaloids: From the Big Bang to the treatment of pediatric acute leukemia

The paradox of Myeloid Leukemia associated with Down syndrome

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome

Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML

Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms

Suchergebnisse filtern